Navigation Links
AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
Date:8/15/2013

Dallas, TX (PRWEB) August 15, 2013

Key R&D trends in the Acute Myeloid Leukemia market include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML. Despite high levels of unmet need, uptake of new drugs will be limited, as KOLs are relatively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period. To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory. Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.

This new research report published in Aug 2013, “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” ( http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html ), focuses on the remaining opportunity in AML exclusive of the acute promyleocytic leukemia (APL) subtype. The scope of this research includes: Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management; Topline AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included; Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the AML therapeutics market; Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available and an analysis of the current and future market competition in the global AML therapeutics market along with insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Buy a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=267301 .

Key questions that this report will help you answer:

  •     Which AML patients have the greatest unmet needs?
  •     What are the R&D strategies drug makers are pursuing in the AML space?
  •     Why has it been so difficult for Pharma to develop successful therapies for AML?
  •     How are players aiming to circumvent difficulties that have historically plagued AML drug development?
  •     What are the most promising pipeline agents for AML? How do their clinical and commercial attributes compare to one another?
  •     What opportunities will remain following the launch of these pipeline agents?
  •     Do KOLs see a role for targeted therapies and immunotherapies in the treatment of AML?

Comprehensive Table of Contents with 59 data Tables and 17 Figures for the report “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” can be accessed at http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html .

Explore more reports on the Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ and on the Healthcare industry @ http://www.reportsnreports.com/market-research/healthcare/ .

About Us:

ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.

Read the full story at http://www.prweb.com/releases/acute-myeloid-leukemia/2017-forecasts-research/prweb11026098.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Lincoln, NE (PRWEB) , ... December 07, 2016 ... ... control systems integration, today announced that it has become a Wonderware Certified System ... Wonderware System Integrator Partner by Schneider Electric Software. , “The System Integrator Partner ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
(Date:12/7/2016)... Dec. 7, 2016  Genprex, Inc. a biopharmaceutical ... therapy treatments, today announced that it has retained ... leading strategic communications and advisory firm, to develop ... program will combine investor relations, public relations and ... the profile of Genprex and its lead candidate ...
(Date:12/7/2016)... Boston, MA and Azusa, CA (PRWEB) , ... ... ... commercial provider of distributed wastewater treatment and resource recovery solutions for industrial facilities, ... Brewing Company , will be the first to use Cambrian’s novel water-energy purchase ...
Breaking Biology Technology:
(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
Breaking Biology News(10 mins):